Eye cancer treatment receives boost from UK regulatory agency

Immunocore

Immunocore Limited, the Milton Park, Oxford-based world leading T cell receptor (TCR) company focused on delivering biological therapies that transform lives, has been granted Promising Innovative Medicines by the UK’s Medicines and Healthcare Products designation for its IMCgp100 for the treatment of patients with metastatic uveal melanoma (eye cancer).

This is based on early Phase I clinical trial data published at the Society for Immunotherapy of Cancer (SITC) annual meeting in November. IMCgp100 will be a suitable candidate for entry into Step II of the Early Access to Medicines Scheme (EAMS) process, for which Immunocore is in a pivotal registrational clinical trial in patients with metastatic uveal melanoma. Following this, IMCgp100 will enter the EAMS scientific opinion assessment step.